Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsPsychopharmacology — benzodiazepine prescribing and tapering

Psych MEQs / SAQs · Psychopharmacology — benzodiazepine prescribing and tapering

Benzodiazepine initiation, conversion and taper (MEQ)

FRANZCP-style MEQ on benzodiazepine prescribing craft: opioid synergy, diazepam substitution, taper scaffold, deprescribing and escalation.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 42-year-old office worker has taken alprazolam 0.5 mg three to four times daily for 18 months for 'stress and sleep,' started after a relationship breakdown. They also take oxycodone PRN for chronic back pain. The GP asks you to take over. (i) Outline the key harms and interaction risks you will counsel on. (ii) Propose a structured outpatient taper plan including equipotency conversion principles and a reduction scaffold with monitoring. (iii) Name non-GABAergic treatments for the underlying anxiety/insomnia. (iv) List three red flags that would trigger specialist or inpatient escalation. (20 marks)

Model answers

(i) Harms and interaction risks (5 marks)

Answer

Counsel on physiological dependence, tolerance, interdose rebound with high-potency short-acting alprazolam, cognitive slowing, falls risk, and protracted withdrawal symptoms after dose cuts.[1][3][10] Emphasise opioid + benzodiazepine synergy: large data link concurrent use with overdose death; avoid casual stacking; review opioid indication and minimise combined CNS depression; naloxone does not reverse benzodiazepine effects.[5][2] Alcohol synergy, driving/occupation risk, and need for a single prescriber/pharmacy reconciliation complete the safety brief.[2][8]

(ii) Structured outpatient taper (7 marks)

Answer

Confirm actual daily alprazolam intake (prescribed vs taken). Convert to approximate diazepam equivalents (teaching anchor: alprazolam ~0.5 mg ≈ diazepam 10 mg — use local tables), stabilise on a long-acting vehicle if interdose symptoms dominate, then reduce about 10–25% of the daily dose every 1–2 weeks, slower near the end, with permission to pause for severe withdrawal.[1][2][3][8] Monitor withdrawal severity, mood/suicidality, alcohol/opioid escalation, falls, and driving. Structured strategies outperform abrupt advice; psychosocial support and education improve success.[4][9][6][7] If seizure or severe crisis: reinstate cover then slower taper — do not leave off all GABA-A PAM activity.[1][8]

(iii) Non-GABAergic plan (4 marks)

Answer

For underlying anxiety: SSRI/SNRI with CBT (or related evidence-based therapy). For insomnia: CBT-I, sleep hygiene, stimulus control; short-term non-GABAergic adjuncts only if needed after specialist judgement. Avoid replacing one automatic GABAergic renewal with another (e.g. chronic Z-drug) without indication review.[10][7][8]

(iv) Escalation red flags (4 marks)

Answer

Any of: history of withdrawal seizures or current seizure; very high-dose or chaotic multi-source use; unstable polysubstance use (alcohol/opioids) with medical risk; failed supervised outpatient taper with severe withdrawal; inability to engage safely in community (e.g. delirium, severe suicidality). Escalate to addiction/medical inpatient pathways with controlled GABA cover.[1][2][8]

References

  1. [1]Soyka M Treatment of Benzodiazepine Dependence N Engl J Med, 2017.PMID 28614686
  2. [2]Brett J, Murnion B Management of benzodiazepine misuse and dependence Aust Prescr, 2015.PMID 26648651
  3. [3]Ashton H The diagnosis and management of benzodiazepine dependence Curr Opin Psychiatry, 2005.PMID 16639148
  4. [4]Voshaar RC, Couvée JE, van Balkom AJ, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis Br J Psychiatry, 2006.PMID 16946355
  5. [5]Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis BMJ, 2017.PMID 28292769
  6. [6]Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial JAMA Intern Med, 2014.PMID 24733354
  7. [7]Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline Can Fam Physician, 2018.PMID 29760253
  8. [8]Brunner E, Chen CA, Klein T, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits J Gen Intern Med, 2025.PMID 40526204
  9. [9]Darker CD, Sweeney BP, Barry JM, et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence Cochrane Database Syst Rev, 2015.PMID 26106751
  10. [10]Guina J, Merrill B Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives J Clin Med, 2018.PMID 29385731